Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NY-ESO-1T Cells · 1 trial · 1 indication
ORR was calculated as the percentage of participants with a confirmed complete response (CR) or partial response (PR) relative to the total number of participants in the analysis population per response evaluation criteria in solid tumors (RECIST) version (v)1.1 as determined by the local investigators.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 treated with NY-ESO-1 T Cells | EXPERIMENTAL | High NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine as the lymphodepleting chemotherapy. |
| Cohort 2 treated with NY-ESO-1 T Cells | EXPERIMENTAL | Low NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine as the lymphodepleting chemotherapy. |
| Cohort 3 treated with NY-ESO-1 T Cells | EXPERIMENTAL | High NYESO-1 expression and the use of cyclophosphamide only for lymphodepletion rather than fludarabine as the lymphodepleting chemotherapy. |
| Cohort 4 treated with NY-ESO-1 T Cells | EXPERIMENTAL | High NY-ESO-1 expression and the use of reduced dose cyclophosphamide plus fludarabine regimen as the lymphodepleting chemotherapy. |
| Name | Type | Description |
|---|---|---|
| NY-ESO-1(c259)T Cells | DRUG | Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0. |
| Fludarabine | DRUG | Fludarabine will be used as lymphodepleting chemotherapy. |
| Cyclophosphamide | DRUG | Cyclophosphamide will be used as lymphodepleting chemotherapy. |
Inclusion Criteria: * Synovial sarcoma that has been treated with standard chemotherapy containing ifosfamide and/or doxorubicin and remains: unresectable or metastatic or progressive/persistent or recurrent disease * Measurable disease * Patients must have proven positive tumor sample for NY-ESO-1...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
NY-ESO-1T Cells is an investigational cell therapy being studied for the treatment of neoplasms, specifically in patients with synovial sarcoma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
NY-ESO-1T Cells is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK.
NY-ESO-1T Cells is in Phase 1 clinical development. It is an investigational therapy, meaning it has not been approved for commercial use and is still undergoing clinical trials to evaluate its safety and efficacy.
NY-ESO-1T Cells has been studied in one completed clinical trial, identified as NCT01343043. This was a pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1ᶜ²⁵⁹T cells in HLA-A2+ patients with synovial sarcoma, conducted in the United States with 50 participants.
Yes, NY-ESO-1T Cells is also known as NY-ESO-1ᶜ²⁵⁹T. The clinical trial NCT01343043 refers to the therapy as genetically engineered NY-ESO-1 specific NY-ESO-1ᶜ²⁵⁹T cells.